Lilly's Keflex patent
Executive Summary
Lilly plans to appeal a New Jersey Federal Court decision that found scope of Lilly's Keflex (cephalexin) patent was not as broad as the company maintained. Lilly filed a patent infringement suit against Vitarine in February. Lilly says the patent in litigation relates to a dense crystalline form of cephalexin, and maintains that the patent does not expire until 1989. The patent covering the cephalexin molecule expired in April.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.